top
Please input keywords
Biocytogen
Innovative technologies drive the R&D of new drugs
Biocytogen(02315.HK) is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMice HiTS Platform).We aspire to accelerate innovation through external partnerships.
Pipeline
To streamline the entire drug development process
We are committed to working with global partners to develop innovative antibody drugs to benefit patients as soon as possible.
テクノロジープラットフォームテクノロジープラットフォームテク
独自のRenMiceベース®プラットフォーム
独自のRenMiceTMプラットフォームに基づいて、我々はGPCR技術プラットフォーム、TCR抗体技術、双抗技術プラットフォームなどを含む抗体薬物発見技術の全プラットフォームシステムを構築し、有効に規模化革新抗体薬物の開発プロセスを加速させる。
Collaborations
Leveraging strengths offering flexibilities pursuing win-win
103therapeutic antibody co-development/out-licensing/transfer agreements
47target-nominated RenMiceTM licensing projects
Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program
Biocytogen granted IDEAYA an option for an exclusive worldwide license for potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) programB7H3/PTK7 co-expression found in multiple solid tumor types, including double-digit percent prevalence in lung, colorectal, and head and neck cancersRational combo opportunities with IDEAYA’s DNA Damage Repair (DDR) pipeline, including IDE161 (PARG)Targeting development candidate nomination in H2 2024 Beijing, China and South San Francisco, CA, July 31, 2024–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that it has entered into an option and license agreement for a potential first-in-class B7H3/PTK7 BsADC program with IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics.“We are thrilled to announce our collaboration with IDEAYA to explore the promising combination of our potential first-in-class ADC and IDEAYA’s DDR small molecules,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This partnership leverages our cutting-edge RenLite® platform and proprietary linker-payload technology to enhance the precision and potency of ADCs. IDEAYA's strong determination and rich experience in drug development make us confident that this therapy could be rapidly advanced to benefit patients.”“The potential first-in-class B7H3/PTK7 topo-I-payload BsADC program has the potential to be developed as a monotherapy agent in multiple solid tumor types, and advances IDEAYA’s broader corporate strategy to enable wholly-owned first-in-class rational combinations at the intersection of ADCs and small molecule DDR-based therapies to deliver greater benefit for patients,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.The agreement grants IDEAYA an option for an exclusive worldwide license from Biocytogen for a potential first-in-class B7H3/PTK7 topo-I-payload BsADC program. B7H3/PTK7 has been found to be co-expressed in multiple solid tumor types, including double-digit percent prevalence in lung, colorectal, and head and neck cancers, among others.Under the terms of the agreement, Biocytogen will receive an upfront fee and upon an option exercise by IDEAYA, be entitled to receive an option exercise fee, development and regulatory milestones and commercial milestone payments, as well as single-digit royalties on net sales. Total potential upfront, option exercise and milestone payments equal an aggregate of $406.5 million, including development and regulatory milestones of $100.0 million.Based on preclinical data, the potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program has the potential to be developed as a monotherapy agent and used in combination with multiple programs in IDEAYA’s pipeline targeting DDR-based therapies, including PARG inhibitor IDE161. A development candidate nomination for the B7H3/PTK7 topoisomerase-I-inhibitor payload BsADC program is targeted for the second half of 2024.About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/ RenLite®/ RenNano®/ RenTCR-mimicTM ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA’s approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.   Biocytogen Contacts Antibody assets and platforms:  BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn Investor and Media Contact IDEAYA BiosciencesAndres Ruiz BrisenoSVP, Head of Finance and Investor Relations  investor@ideayabio.com
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline
Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite® platformAgreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCsBiocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 millionPrague, Czech Republic and Beijing, China, July 16, 2024 SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, and Biocytogen (HKEX: 02315), a global biotech company focused on the discovery of novel antibody therapeutics, today announced a research collaboration and exclusive option and license agreement.The agreement grants SOTIO the option to license multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite® platform, which SOTIO will use to develop next-generation antibody-drug conjugates (ADCs) targeting solid tumors. The agreement also includes an option for SOTIO to leverage Biocytogen’s proprietary ADC platform. Biocytogen will be eligible to receive upfront, development, and commercial milestones and royalties on net sales on a product-by-product basis.“SOTIO’s powerful ADC platform brings together multiple technologies, allowing us to tailor our therapeutics to meet the needs of specific cancer types. Specifically, exploiting bispecific targeting in the context of our ADC approaches to improve precision targeting and overcome tumor heterogeneity is particularly appealing,” said Martin Steegmaier, Ph.D., chief scientific officer of SOTIO. “This agreement with Biocytogen complements our existing collaborations with Synaffix, LigaChem, and NBE-Therapeutics, providing SOTIO with access to fully human antibodies from Biocytogen’s state-of-the-art in vivo discovery platform. With the first targets for a bispecific program already selected, we are well-positioned to expand our ADC pipeline and the therapeutic possibilities for patients with solid tumors.”Under the terms of the agreement, Biocytogen is eligible to receive upfront and potential milestone payments worth up to $325.5 million, plus low single-digit royalties on net sales. SOTIO and Biocytogen will collaborate closely during the research phase of the bispecific programs. SOTIO will be responsible for non-clinical and clinical development, manufacturing, and commercialization of the ADC products.“We are eager to deploy Biocytogen’s cutting-edge tools for antibody discovery to support SOTIO’s exciting ADC development plans,” said Yuelei Shen, Ph.D., president and chief executive officer of Biocytogen. “Our unique RenMice® platforms allow us to discover fully human antibodies with high affinity, low immunogenicity, and favorable developability. We look forward to working with SOTIO to advance novel therapeutics that have the potential to improve cancer treatment.”About SOTIO SOTIO Biotech (SOTIO) is shaping the future of targeted cancer therapies by translating compelling science into patient benefit. The SOTIO pipeline includes three clinical-stage programs: SOT102, a next-generation Claudin-18.2-targeted antibody-drug conjugate; BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors; and SOT201, a next-generation PD-1-targeting immunocytokine. SOTIO is a member of the PPF Group. SOTIO is a registered trademark of SOTIO Biotech a.s. in selected countries. For more information, please visit the company’s website at www.sotio.com.About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice®, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.Company contacts: Richard Kapsa                                    Head of Communications                      SOTIO Biotech a.s.                             T: +420 224 174 448                           M: +420 603 280 971                           E: kapsa@sotio.com                             Chaoshe Guo Vice President  (Global Head of Business Development) Biocytogen Pharmaceuticals (Beijing) Co., Ltd. M: +86 10-5696 7680 E: chaoshe.guo@bbctg.com.cn Media contacts: Lisa Raffensperger                               Ten Bridge Communications (SOTIO)     M: +1 (617) 903-8783                          E: lisa@tenbridgecommunications.com   Yanan Liu Biocytogen Pharmaceuticals (Beijing) Co., Ltd. M: +86 10-5696 7680 E: yanan.liu@bbctg.com.cn
Biocytogen Enters into Evaluation and Potential Licensing Agreement with BioCopy for TCR-mimic Antibodies
Beijing, China, May 6, 2024 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG (“BioCopy”), a research-based biotechnology company headquartered in Basel, Switzerland. The agreement grants BioCopy access to fully human TCR-mimic antibodies targeting an intracellular antigen generated by Biocytogen’s proprietary RenTCR-mimicTM mice. BioCopy will conduct an evaluation and retain the option to license these antibodies for the development of novel cancer therapies.“We are glad to provide BioCopy with our TCR-mimic antibodies,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Our in vivo matured TCR-mimic antibodies demonstrated favorable affinity and excellent specificity. Combined with BioCopy’s expertise in TCR-mimic antibody screening and engager development, we are optimistic that our collaboration will generate novel drugs that benefit cancer patients.”BioCopy will use Biocytogen’s TCR-mimic antibodies and test them against promising intracellular tumor associated antigens. Here, BioCopy will use its automated end-to-end platform for the optimization of multispecific biotherapeutics to further develop these TCR-mimic antibodies into next-generation oncological drugs.About Biocytogen’s TCR-mimic Antibody Discovery Platform Biocytogen’s TCR-mimic platform focuses on the discovery of fully human antibodies to intracellular targets that are presented on the cell surface by MHC class I molecules. Leveraging proprietary RenTCR-mimicTM (HLA/RenMab) mice and specialized immunization protocols, Biocytogen’s platform is designed to generate TCR-mimic antibodies that are highly specific for peptide/HLA complexes and not HLA itself. Using high-throughput antibody screening platform, Biocytogen swiftly identifies TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients to overcome tumor immune escape. Currently, antibody hits for multiple intracellular targets, including TAAs, cancer-testis antigens, mutated protein antigens, and viral protein antigens, are being evaluated in vivo and in vitro. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.About BioCopy BioCopy is a multinational company headquartered in Switzerland with a state-of-the-art R&D facility in Germany. The company focuses on biotherapeutic drug discovery and development using their end-to-end automated, AI-powered platform. BioCopy is convinced that cancer can be cured with ingenuity and AI, supported by the extraordinary power of our body’s own immune system. With the company’s unique platform BioCopy is working continuously to develop next generation biotherapeutic drug candidates with unprecedented efficacy and safety, transforming today’s pharmaceutical industries.Website: www.biocopy.comBiocytogen Contacts Antibody assets and platforms: BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn
会社ニュース
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
IDEAYA has exercised the option for an exclusive worldwide license on Biocytogen’s potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (BsADC), BCG034 (IDE034)This milestone further validates Biocytogen’s proprietary RenLite® antibody discovery platform, demonstrating its potential to advance innovative therapies for patientsIND application for IDE034 expected in 2025 to enable first-in-human clinical evaluation of B7H3/PTK7 topo-I-payload BsADC programIDE034 has the potential to be developed as a monotherapy and in combination with IDEAYA's PARG inhibitor IDE161 BEIJING, China and South San Francisco, CA, November 11, 2024– Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, has exercised the option for an exclusive worldwide license for Biocytogen's B7H3/PTK7 BsADC program, IDE034, and has nominated it as a development candidate.“We are excited that IDEAYA has chosen to exercise their option to license the worldwide rights to our B7H3/PTK7 BsADC IDE034, which incorporates our proprietary topoisomerase linker-payload,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This important milestone in our collaboration further validates the capabilities of Biocytogen’s RenLite® platform, bringing us closer to impactful treatments for patients with solid tumors. We look forward to supporting IDEAYA as they advance this program to clinical stages.”Michael White, Ph.D., Chief Scientific Officer of IDEAYA Biosciences, commented, “We are pleased to nominate IDE034 as a development candidate. This promising, potential first-in-class B7H3/PTK7 topo-I-payload bispecific ADC has shown significant tumor regression in preclinical models. The high prevalence of B7H3/PTK7 co-expression in solid tumors such as lung, colorectal, and head and neck cancers underscore its potential as both a monotherapy and in combination with our PARG inhibitor, IDE161.”IDEAYA is targeting an Investigational New Drug (IND) submission to the U.S. FDA in 2025 for IDE034, pending the completion of ongoing preclinical and IND-enabling studies, to facilitate the initiation of first-in-human trials.Under the option and license agreement between Biocytogen and IDEAYA, Biocytogen will receive upfront and option exercise fees, along with additional development and regulatory milestone payments, commercial milestone payments, and royalties on net sales, totaling $406.5 million, including up to $100 million in development and regulatory milestone payments.Based on the Human Protein Atlas database, B7H3/PTK7 has been reported to be co-expressed in multiple solid tumor types, including in lung, colorectal, and head and neck cancers at approximately 30%, 46% and 27%, respectively.About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2024, approximately 150 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and nearly 50 target-nominated RenMice® licensing projects have been established with over 60 global pharmaceutical and biotech companies, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.Biocytogen Media Contacts Antibody assets and platforms:  BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn
2024.11.11
Visit our booth #319 and 5 posters at SITC 2024!
Biocytogen (HKEX: 02315) is excited to announce our attendance at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston, TX, from November 6-10, 2024!Additionally, we invite you to stop by booth #319 to meet our team and learn how our antibody assets, fully human antibody discovery platform, animal/cell models, and pharmacology services can help accelerate your drug development process.Exhibition Sessions:Booth Number: #319Date: November 8-10, 2024 (Friday-Sunday)Location: George R. Brown Convention Center, Houston, TXPoster Sessions:Date: November 7-9, 2024 (Thursday-Saturday)Location: Exhibit Halls A & B, George R. Brown Convention CenterBioMice - Preclinical Models and Services DivisionPreclinical pharmacology services, including in vivo efficacy evaluation, in vivo pharmacology analysis, PK/PD analysis, diagnosis/pathology/toxicology evaluations3300+ World-class novel animal and cell modelsGene editing mouse/cell line servicesPoster Presentations:Friday, Nov. 8:#3: Humanized HER2-expressing tumor cells established syngeneic models for evaluating HER2 antibody-drug conjugate (ADC) therapy#7: The pairing of CD200 humanized cancer cells with CD200 and CD200R double humanized mice for the preclinical evaluation of the combination of anti-human CD200 antibodies and immune checkpoint drugsSaturday, Nov. 9:#4: Establishing a tumor cell model to evaluate the bystander effect of antibody-drug conjugate (ADC) therapies#6: A novel IL12Rβ1 and IL12Rβ2 humanized mouse model for preclinical efficacy and toxicity evaluation of human IL-12 analogsRenBiologics - Innovative Antibody Drug Discovery DivisionPowered by Biocytogen’s proprietary RenMiceTM fully human antibody discovery platformEnables the development of monoclonal antibodies, bispecific antibodies, bispecific ADCs, nanobodies, and TCR-like antibodiesOffers various commercial models, including antibody licensing, transfer, and co-development partnershipsFeatures a shelf library of over 400,000 fully human antibody sequences targeting around 1,000 antigens, with approximately 150 partnerships already establishedPoster Presentations:Thursday, Nov. 7 & Friday, Nov. 8:#1049: TAA antibody library and novel linker/payload BLD1102 for ADC, bispecific ADC and nanobody-drug conjugate developmentWe look forward to exploring collaboration opportunities that can support your R&D needs.To learn more, please click here to contact us.
2024.11.01
Visit our booth #208 and explore our posters at World ADC San Diego!
Biocytogen (HKEX: 02315) is excited to attend World ADC San Diego 2024 at the Town & Country Resort, San Diego, CA, from November 4-7. Our Business Development and Licensing Team looks forward to meeting you in person at Booth #208! We’ll also be showcasing two posters highlighting Biocytogen’s groundbreaking advancements in antibody-drug conjugate (ADC) projects. Don’t miss the chance to schedule a 1-on-1 meeting with us!Exhibition Session: Booth Number: #208Poster Session: Time: 6:30 p.m., TuesdayLocation: The Exhibition HallPoster #31: Novel Bispecific ADC Targeting SEZ6 and B7H3 for the Treatment of Small Cell Lung Cancer (SCLC)Poster #32: BCG014: A CDH3-Targeting ADC with a Novel TOPO1 Inhibitor PayloadAntibody-drug conjugates (ADCs) significantly outperform traditional monoclonal antibody therapies by precisely targeting tumor cells and directly delivering cytotoxic agents. This targeted approach boosts therapeutic efficacy while minimizing toxicity to healthy cells, reducing side effects, and improving patient tolerability.Building on these advantages, bispecific ADCs—which target two distinct tumor antigens—offer even greater targeting precision and efficacy. This dual targeting provides broader, more sustained cytotoxic activity against heterogeneous tumors. However, the complex structure of bispecific ADCs also introduces greater challenges in development and production.To address these challenges, Biocytogen has independently developed the RenLite® platform, which leverages common light chain technology to effectively prevent mismatches between light and heavy chains during bispecific antibody assembly. In addition, Biocytogen owns the proprietary Linker & Payload platform BLD1102. Utilizing RenLite and the new bispecific ADC platform, we have generated a large antibody library against more than 200 tumor-associated antigens (TAAs) and established over 400 antibody discovery projects. We look forward to discussing licensing opportunities for new antibody molecules and antibody discovery platforms with you.Please click here to schedule a 1-on-1 meeting with us to learn more.
2024.11.01